ArticleProbiotics and antimicrobial proteins2026
Lactiplantibacillus Plantarum CKDB008 and Lacticaseibacillus Rhamnosus LDTM7511 Attenuate Visceral Hypersensitivity and Suppress Serum IgE in an Acetic Acid-Induced IBS-Like Rat Model.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction characterized by visceral hypersensitivity, impaired intestinal barrier, immune activation, and gut microbiota dysbiosis, for which standardized treatment remains limited. In this study, we evaluated Lactiplantibacillus plantarum CKDB008 (LP) and Lacticaseibacillus rhamnosus LDTM7511 (= CKDB511; LR), each administered at low (1 × 10⁸ colony forming unit [CFU]/day) and high (1 × 10⁹ CFU/day) doses for 14 days in an acetic acid-induced post-inflammatory IBS-like rat model. Visceral hypersensitivity was assessed by the abdominal withdrawal reflex (AWR) test, and serum and distal colonic markers of stress, immunity, barrier function, and gut microbiota were analyzed. LR consistently attenuated visceral hypersensitivity at both doses, whereas LP reduced serum cortisol more strongly at the high dose, indicating distinct response profiles across endpoints. Serum IgE was significantly reduced in all probiotic-treated groups regardless of strain or dose (P < 0.01), and distal colonic zonula occludens-1 expression was upregulated primarily in the LR-treated groups, reflecting limited and marker-specific modulation of barrier-related readouts. In the gut microbiota, Kineothrix alysoides was significantly depleted in the low-dose LP group after false discovery rate correction (Q < 0.05), with a positive correlation observed between its abundance and AWR area under the curve. Predicted microbial pathway profiles also showed changes primarily in the LR-treated groups relative to IBS at the suggestive level. Collectively, these findings provide preliminary preclinical evidence that LP and LR alleviate several IBS-related phenotypes in this rat model, supporting their further evaluation as candidate probiotic strains for IBS.
Indexed as
Identifiers
42853311What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.